Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Industrial Goods — Chemicals. Per the activity note to the FY2024 annual report, the company manufactures and sells biological active substances and perfumery products. Located in Mtskheta district.
| Ratio | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 30.9% | 34.3% | 33.0% | 40.3% | 39.3% |
| EBITDA Margin | 1.4% | 15.3% | 14.3% | -1.1% | -41.5% |
| EBITDAR | 26 | 989 | 1,142 | 11 | -695 |
| EBITDAR Margin | 1.4% | 15.3% | 15.1% | 0.2% | -37.1% |
| EBIT Margin | 1.0% | 15.1% | 14.0% | -1.7% | -43.1% |
| Net Profit Margin | -59.1% | 14.4% | 18.3% | -5.9% | -100.2% |
| Operating Expense % of Sales | 29.5% | 18.9% | 18.6% | 41.5% | 80.8% |
| Returns | |||||
| Return on Assets (ROA) | -17.9% | 12.8% | 11.8% | -2.9% | -14.9% |
| Return on Equity (ROE) | N/A | N/A | N/A | N/A | N/A |
| ROIC [EBIT / Invested Capital] | 0.4% | 16.5% | 9.8% | -0.9% | -7.4% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 118.6% | 117.2% | 96.0% | 95.4% | 108.2% |
| Debt-to-Equity | -2.66x | -4.85x | -30.78x | -15.78x | -5.29x |
| Debt-to-EBITDA | 275.52x | 8.57x | 10.43x | N/A | N/A |
| Equity-to-Assets | -44.5% | -24.2% | -3.1% | -6.1% | -20.4% |
| Net Debt | 7,006 | 7,625 | 11,094 | 10,905 | 13,503 |
| Cash & Equivalents | 116 | 846 | 182 | 32 | 103 |
| Total Debt | 7,122 | 8,472 | 11,276 | 10,938 | 13,606 |
| Liquidity & working capital | |||||
| Current Ratio | 1.07x | 0.76x | 3.11x | 4.21x | 6.38x |
| Quick Ratio | 0.41x | 0.76x | 3.11x | 4.21x | 6.38x |
| Cash Ratio | 0.04x | 0.15x | 0.06x | 0.01x | 0.08x |
| Total Current Assets | 3,289 | 4,298 | 8,819 | 9,138 | 8,569 |
| Total Current Liabilities | 3,083 | 5,624 | 2,838 | 2,169 | 1,343 |
| Inventory | 2,023 | N/A | N/A | N/A | N/A |
| Trade Receivables | 63 | 421 | 4,592 | 5,900 | 7,532 |
| Trade Payables | 487 | 66 | 830 | 1,196 | 1,343 |
| Net Working Capital | 206 | -1,326 | 5,981 | 6,969 | 7,226 |
| Net Working Capital % of Revenue | 11.3% | -20.6% | 79.2% | 126.8% | 385.8% |
| Trade Working Capital | 1,598 | 354 | 3,762 | 4,704 | 6,189 |
| Trade Working Capital % of Revenue | 87.9% | 5.5% | 49.8% | 85.6% | 330.5% |
| Change in Trade Working Capital | N/A | -1,244 | 3,407 | 942 | 1,485 |
| Turnover & efficiency | |||||
| Inventory Turnover | 0.62x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 587.7 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 29.00x | 15.32x | 1.64x | 0.93x | 0.25x |
| Days Sales Outstanding (DSO) | 12.6 | 23.8 | 222.1 | 391.7 | 1468.0 |
| Payables Turnover | 2.58x | 63.79x | 6.09x | 2.74x | 0.85x |
| Days Payable Outstanding (DPO) | 141.6 | 5.7 | 59.9 | 133.1 | 430.9 |
| Cash Conversion Cycle | 458.7 days | 18.1 days | 162.2 days | 258.6 days | 1037.1 days |
| Asset Turnover | 0.30x | 0.89x | 0.64x | 0.48x | 0.15x |
| Cash flow & dividends | |||||
| Operating Cash Flow | -568 | -122 | -3,994 | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | -692 | -604 | -4,172 | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | -2198.2% | -12.4% | -369.4% | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.